KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Non Operating Income (2016 - 2025)

CRISPR Therapeutics AG's Non Operating Income history spans 11 years, with the latest figure at $24.8 million for Q4 2025.

  • For Q4 2025, Non Operating Income fell 11.48% year-over-year to $24.8 million; the TTM value through Dec 2025 reached $86.6 million, down 16.65%, while the annual FY2025 figure was $86.6 million, 16.65% down from the prior year.
  • Non Operating Income for Q4 2025 was $24.8 million at CRISPR Therapeutics AG, down from $26.2 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $28.0 million in Q4 2024 and bottomed at $363000.0 in Q1 2022.
  • The 5-year median for Non Operating Income is $16.0 million (2023), against an average of $14.5 million.
  • The largest annual shift saw Non Operating Income crashed 81.43% in 2022 before it skyrocketed 3410.19% in 2023.
  • A 5-year view of Non Operating Income shows it stood at $2.2 million in 2021, then surged by 422.99% to $11.5 million in 2022, then skyrocketed by 74.04% to $20.0 million in 2023, then soared by 39.91% to $28.0 million in 2024, then fell by 11.48% to $24.8 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Non Operating Income are $24.8 million (Q4 2025), $26.2 million (Q3 2025), and $22.1 million (Q2 2025).